Vivo Bio Tech consolidated net profit rises 43.24% in the March 2025 quarter
Vivo Bio Tech Limited, a leading biotechnology and pharmaceutical company, has reported a robust financial performance for the quarter ended March 2025. The company’s consolidated net profit surged by 43.24% year-on-year (YoY), reflecting strong operational efficiency, increased demand for its products, and strategic business expansions. This impressive growth highlights Vivo Bio Tech’s resilience in a competitive … Read more